Halozyme outlines $1.71B–$1.81B 2026 revenue target as new subcutaneous technologies expand pipeline [Seeking Alpha]
Halozyme Therapeutics, Inc. (HALO)
Last halozyme therapeutics, inc. earnings: 2/24 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
halozyme.com/investors/default.aspx
Company Research
Source: Seeking Alpha
Helen Torley, President and CEO, highlighted that "2025 was one of the most significant and value-creating years in Halozyme's history," citing the expansion of the portfolio from two to four subcutaneous drug delivery technologies Quick Insights Halozyme's portfolio expansion to four drug delivery technologies positions it for durable long-term revenue growth and broader biopharma partnerships. Projected 2026 growth is driven by ENHANZE-enabled products like DARZALEX SC, PHESGO, and VYVGART Hytrulo, as well as new royalty streams and integrated acquisitions. Halozyme is securing new agreements in obesity and IBD, expecting to renew expiring partnerships, and leveraging new technologies to strengthen and extend its royalty streams. Recommended For You More Trending News
Show less
Read more
Impact Snapshot
Event Time:
HALO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HALO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HALO alerts
High impacting Halozyme Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HALO
News
- Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at TD Cowen.MarketBeat
- Halozyme Therapeutics Inc (HALO) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]Yahoo! Finance
- Halozyme Therapeutics, Inc. (HALO) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Halozyme Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Halozyme (HALO) Q4 2025 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
HALO
Earnings
- 2/17/26 - Miss
HALO
Sec Filings
- 2/17/26 - Form 4
- 2/17/26 - Form 4
- 2/17/26 - Form 4
- HALO's page on the SEC website